Purpose: To evaluate our institutional experience with Mycobacterium abscessus infections occurring in lung transplant recipients (LTR).
| INTRODUC TI ON
Mycobacterium abscessus is a rapidly growing, environmental non-tuberculous mycobacteria (NTM) that can cause serious opportunistic infections in immunosuppressed patients such as transplant recipients, which may result in severe complications including death. M. abscessus has been detected in potable tap water 1 and in heater-cooler units used for cardiac operations, 2 and can be resistant to disinfectants, all of which may facilitate infection in surgical patients. 3 Although Mycobacterium avium complex (MAC) is the most common NTM species responsible for disease in humans, M. abscessus is the most common rapidly growing NTM to cause respiratory infections in the United States 3 ; it is also more difficult to eradicate, 4 and has a high risk of recurrence. 3, 5, 6 In addition to drug resistance, toxicities of anti-mycobacterial medications have limited treatment options for M. abscessus. Because of the challenges in dealing with this infection, M. abscessus infection has been considered by some authors to be a contraindication to lung transplantation (LT). 7, 8 Mycobacterium abscessus infections are uncommon and in the United States account for only 2.6%-13% of all mycobacterial pulmonary infections 3 (ie, <1 M. abscessus pulmonary infection per 100 000 population). However, M. abscessus infections are becoming increasingly more prevalent worldwide, with a significant increase in their incidence seen in Taiwan, the United States, and Australia. 9 The impact of pre-or post-transplant M. abscessus infections in lung transplant recipients (LTR) is not well understood since large database or institutional series studies specific to this organism are scarce in the literature. Most accounts of M. abscessus infections in the lung transplant setting have been from case reports 10 or studies that considered all NTM infections together as a single group of pathogens. 11, 12 The purpose of this study was to understand the impact of M. abscessus infections in patients undergoing LT at our institution. 
| MATERIAL S AND ME THODS

| Immunosuppression protocol
| Statistics
Continuous patients and the rest of the LTR in our institutional database were then compared using log-rank test. P values were considered significant when <.05. Microbiologic characteristics, antibiotic therapy, duration of treatment, and outcomes including complications are presented in Table 2 . Antibiotic susceptibilities are shown in Table 3 .
| RE SULTS
Medication regimens and duration of treatment differed for every patient. From two to six different anti-microbials were used in various combinations. Amikacin, azithromycin, clarithromycin, ce- to discontinuation of all therapy. Renal insufficiency evidenced by rapidly increasing serum creatinine occurred in one patient and resolved after amikacin was discontinued. Linezolid was associated with severe cytopenia in one patient and was discontinued.
In another patient, GI intolerance (severe C. difficile-negative diarrhea) occurred after several weeks of therapy and resolved after clarithromycin was discontinued. 
| D ISCUSS I ON
NTM have been episodically isolated in about 9%-22% of LTR when followed long term, with MAC being the most common species (approx. 70%) followed by M. abscessus (approximately 9% 16 However, this survey had only a 50% response rate and did not include the institutions from the South Eastern United States where the infection is considered to be endemic. 20 The higher incidence of M. abscessus in our transplant database may be related to either our location in this en- NTM to be a risk factor for increased mortality after transplantation. 13 Even the few studies that were specific to M. abscessus infections did not find long-term survival to be adversely affected. [16] [17] [18] This discrepancy in outcomes is not surprising given the heterogeneity of transplant recipients, the rare nature of the infection and the pooling of all NTM into a single group. Since most lung recipients described in the literature with M. abscessus infection had CF and hence underwent double lung transplant (DLTx), it remained to be seen whether single lung transplant (SLTx) recipients would be at risk of developing more refractory and fulminant infections due to the remaining contralateral diseased native lung. In our study, the four SLTx recipients with
M. abscessus infection had similar manifestations of the infection when compared to DLTx recipients.
Mycobacterium abscessus infections occurring in the breast, skin, and bone marrow after LT have been reported in literature. 7, 16 In the majority of these case reports, the infections appeared to manifest in the chest wall close to the thoracotomy incisions, which may indicate a direct contamination during transplantation. However, the infection can occur in any soft or osseous tissue that does not necessarily have to be in direct continuity with the surgical field, resulting in mild to fatal complications. 16, 22, 23 Our experience is similar to that reported from A strict surveillance protocol with bronchoscopic cultures to actively detect M. abscessus (and other NTM) should be part of any LT program. Surveillance should also include periodic radiologic imaging preferably with CT scans, which are more sensitive than chest x-rays for early changes related to M. abscessus infection. 13, 16, 25 Observation with close surveillance can be considered for colonized patients in the absence of symptoms and radiographic abnormal- 
TA B L E 1 Patient demographics and clinical features of Mycobacterium abscessus and Mycobacterium chelonae/abscessus infection
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Mycobacterium abscessus is considered extremely difficult to eradicate with non-clarithromycin-based antibiotic therapy, as reported by Griffith et al. 26 Empiric therapy consists of a threedrug clarithromycin-based combination therapy, usually combined with intravenous cefoxitin, amikacin, or imipenem for the first few weeks of treatment, followed by further adjustment of the antibiotic regimen after review of the susceptibility test results. 8, 20 Most of our isolates were not susceptible to cefoxitin or imipenem and perhaps other alternatives like tigecycline or linezolid should be considered for empiric therapy. Although aggressive therapy may be warranted for transplant recipients, the side effects and toxicities of anti-mycobacterial medications should be considered, when determining appropriate management. 27 The optimal duration of treatment for M. abscessus infection in transplant recipients has not been established, at least 12 months of negative sputum cultures while on multidrug antibiotic therapy has been proposed. 8 Jeon et al 27 found 58% of patients with M. abscessus lung infections remained sputum negative at 12 months when treated with multidrug therapy. With appropriate treatment, long-term sputum negativity can be achieved but local and distant recurrences can occur even years later, as seen in our study. Surgical resection has been used as a modality of treatment for refractory or cavitary disease. 16, 28 One of our patients underwent re-transplantation for graft failure secondary to M. abscessus infection and was able to achieve cure although he was re-infected with a different strain 13 months after completion of therapy and another patient underwent amputation of a lower extremity for osteomyelitis.
Limitations of our study include its retrospective nature even though the data were prospectively collected. our study has a small patient sample, it is nevertheless an important one since, to the best of our knowledge it is the largest published single-institution study specific to LT-related M. abscessus infections. 
| CON CLUS ION
